Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
1999 2
2000 3
2001 3
2002 2
2003 2
2004 1
2010 1
2011 1
2012 1
2013 2
2014 1
2015 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Androgen pathway dysregulation in BRCA1-mutated breast tumors.
Berns EM, Dirkzwager-Kiel MJ, Kuenen-Boumeester V, Timmermans M, Verhoog LC, van den Ouweland AM, Meijer-Heijboer H, Klijn JG, van der Kwast TH. Berns EM, et al. Among authors: verhoog lc. Breast Cancer Res Treat. 2003 May;79(1):121-7. doi: 10.1023/a:1023347409599. Breast Cancer Res Treat. 2003. PMID: 12779088
Loss of E-cadherin is not a necessity for epithelial to mesenchymal transition in human breast cancer.
Hollestelle A, Peeters JK, Smid M, Timmermans M, Verhoog LC, Westenend PJ, Heine AA, Chan A, Sieuwerts AM, Wiemer EA, Klijn JG, van der Spek PJ, Foekens JA, Schutte M, den Bakker MA, Martens JW. Hollestelle A, et al. Among authors: verhoog lc. Breast Cancer Res Treat. 2013 Feb;138(1):47-57. doi: 10.1007/s10549-013-2415-3. Epub 2013 Jan 22. Breast Cancer Res Treat. 2013. PMID: 23338761
Survival in hereditary breast cancer associated with germline mutations of BRCA2.
Verhoog LC, Brekelmans CT, Seynaeve C, Dahmen G, van Geel AN, Bartels CC, Tilanus-Linthorst MM, Wagner A, Devilee P, Halley DJ, van den Ouweland AM, Meijers-Heijboer EJ, Klijn JG. Verhoog LC, et al. J Clin Oncol. 1999 Nov;17(11):3396-402. doi: 10.1200/JCO.1999.17.11.3396. J Clin Oncol. 1999. PMID: 10550133
Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation.
Meijers-Heijboer H, van Geel B, van Putten WL, Henzen-Logmans SC, Seynaeve C, Menke-Pluymers MB, Bartels CC, Verhoog LC, van den Ouweland AM, Niermeijer MF, Brekelmans CT, Klijn JG. Meijers-Heijboer H, et al. Among authors: verhoog lc. N Engl J Med. 2001 Jul 19;345(3):159-64. doi: 10.1056/NEJM200107193450301. N Engl J Med. 2001. PMID: 11463009 Free article.
Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk.
Brekelmans CT, Seynaeve C, Bartels CC, Tilanus-Linthorst MM, Meijers-Heijboer EJ, Crepin CM, van Geel AA, Menke M, Verhoog LC, van den Ouweland A, Obdeijn IM, Klijn JG; Rotterdam Committee for Medical and Genetic Counseling. Brekelmans CT, et al. Among authors: verhoog lc. J Clin Oncol. 2001 Feb 15;19(4):924-30. doi: 10.1200/JCO.2001.19.4.924. J Clin Oncol. 2001. PMID: 11181654
18 results